BDRX
Biodexa Pharmaceticals
NASDAQ: BDRX · HEALTHCARE · BIOTECHNOLOGY
$3.80
-2.04% today
Updated 2026-06-05
Market cap
$2.68M
P/E ratio
—
P/S ratio
10.16x
EPS (TTM)
$-3.36
Dividend yield
—
52W range
$3 – $67
Volume
2.9M
Biodexa Pharmaceticals (BDRX) Financial statements
SEC filings — annual and quarterly data.
Profit margin
0.00%
Operating margin
0.00%
ROE
-106.26%
ROA
-32.80%
Debt/equity
0.01x
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2012 | — | $-3.99M | — | — | — |
| 2013 | $147000.00 | $-4.08M | 100.00% | -3,060.54% | -2,778.23% |
| 2014 | $157000.00 | $-8.82M | 100.00% | -4,914.01% | -5,619.11% |
| 2015 | $1.38M | $-10.10M | 94.91% | -733.96% | -734.47% |
| 2016 | $1.32M | $-6.16M | -484.28% | -729.55% | -465.68% |
| 2017 | $989000.00 | $-11.71M | -742.16% | -1,190.70% | -1,183.52% |
| 2018 | $1.94M | $-10.37M | -382.92% | -609.65% | -534.98% |
| 2019 | $674000.00 | $-10.09M | -1,063.65% | -1,679.23% | -1,496.29% |
| 2020 | $343000.00 | $-22.19M | -1,669.10% | -6,717.20% | -6,469.10% |
| 2021 | $578000.00 | $-5.46M | -705.19% | -1,210.73% | -944.64% |
| 2022 | $699000.00 | $-7.66M | -631.19% | -1,277.83% | -1,095.28% |
| 2023 | $381000.00 | $-7.08M | -967.45% | -2,103.41% | -1,858.01% |
| 2024 | $0.00 | $-5.73M | — | — | — |
| 2025 | $0.00 | $-6.24M | — | — | — |
Frequently asked questions
What is Biodexa Pharmaceticals's revenue?
Biodexa Pharmaceticals's trailing twelve-month revenue is $83000.00. Revenue is the top line the whole model builds on, and at this scale the question shifts from how fast it grows to whether margins hold as it compounds.
How much free cash flow does BDRX generate?
BDRX produced $-5.40M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.
Is BDRX's balance sheet healthy?
BDRX holds $8.52M in cash and equivalents against — in long-term debt, on $11.38M of shareholder equity. That debt is best read against the cash flow the business throws off each year.